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ABSTRACT  23 
Background & aims: Broccoli sprouts represent an interesting choice of healthy food 24 
product as they are rich in glucosinolates and their cognate bioactive metabolites, 25 
isothiocyanates able to counteract the negative effects of diverse pathologies. As obesity 26 
is linked to an inflammatory component, the aim of the study was to evaluate the anti-27 
inflammatory action of broccoli sprouts in overweight adult subjects.  28 
Methods: An in vivo controlled study was performed in 40 healthy overweight subjects 29 
(ClinicalTrials.gov ID NCT 03390855). Treatment phase consisted on the consumption 30 
of broccoli sprouts (30 g/day) during 10 weeks and the follow-up phase of 10 weeks of 31 
normal diet without consumption of these broccoli sprouts. Anthropometric parameters 32 
as body fat mass, body weight, and BMI were determined. Inflammation status was 33 
assessed by measuring levels of TNF-α, IL-6, IL-1β and C-reactive protein.  34 
Results: IL-6 levels significantly decreased (mean values from 4.76 pg/mL to 2.11 35 
pg/mL with 70 days of broccoli consumption, p < 0.001) and during control phase the 36 
inflammatory levels were maintained at low grade (mean values from 1.20 pg/mL to 37 
2.66 pg/mL, p < 0.001). C-reactive protein significantly decreased as well. 38 
Conclusions: This study represents an advance in intervention studies as the broccoli 39 
sprouts were included in a daily dietary pattern in quantities that reflect a real 40 
consumption. Further studies are necessary to elucidate the role of this healthy rich and 41 
nutritious food product, but these promising results support the current evidence on the 42 
healthy properties of Brassica varieties. 43 
  44 
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INTRODUCTION 45 
Nowadays there is an increasing demand by consumers on healthy food products 46 
prepared in convenient forms, simple to use and not containing additives. In this sense, 47 
broccoli sprouts (Brassica oleraceae var. italica) are a good option, as they are the main 48 
dietary source of glucosinolates, nitrogen-sulfur compounds, and phenolic derivatives 49 
(flavonoid glycosides, and hydroxycinnamic acids), vitamins A, C, E, K and minerals 50 
[1]. Glucosinolates are derivatives from amino acids and particularly abundant in 51 
Brassica species and are believed to be responsible of the biological effects attributed to 52 
these vegetables. Cultivar conditions can affect and improve the biosynthesis of these 53 
secondary metabolites in the plant, favouring their storage in the sprouts. Broccoli 54 
sprouts contain 10- to 50-fold higher concentrations of glucosinolates than the mature 55 
broccoli  [2].  56 
Isothiocyanates are degradation products from glucosinolates formed by the hydrolytic 57 
action of myrosinase vegetable enzyme when the vegetable structure is crushed, e.g. 58 
during mastication process. Hydrolysis can also be performed by gastrointestinal 59 
enzymes during digestion; the metabolic conversion of glucosinolates to isothiocyanates 60 
is a crucial step for the benefits observed with the consumption of Brassica vegetables 61 
[3]. Most of these reported effects are linked to anti-cancer properties and  62 
epidemiological studies have evidenced a decrease in the risk of cancer with the intake 63 
of cruciferous foods [4, 5]. Human clinical studies have mainly focused on these 64 
antitumoral activities, with mechanisms including the upregulation of phase II 65 
detoxification enzymes, as well as the direct action on cell cycle, causing apoptosis of 66 
cancer cells [6] [7]. There is less evidence on the anti-inflammatory properties of 67 
cruciferous vegetables in humans.  68 
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A non-communicable disease of high prevalence in Western societies is obesity. 69 
Nowadays it is assumed that obesity is a condition characterized by a chronic low-grade 70 
inflammation status. Levels of pro-inflammatory mediators as IL-6, TNF-α and C-71 
reactive protein are increased with the higher visceral adiposity and all of them are risk 72 
factors for cardiovascular diseases, metabolic syndrome and diabetes [8]. The 73 
permanent low-grade of inflammation is a response of the organism to the imbalance in 74 
the nutrient due to energy excess and it is manifested in the development of insulin 75 
resistance and type 2 diabetes [9]. Dietary interventions able to reduce the inflammatory 76 
conditions linked to obesity may improve health conditions of overweight population.  77 
The hypothesis of our research is that broccoli sprouts are able to reduce the 78 
inflammatory status in overweight subjects due to their content in phytochemicals, 79 
mainly glucosinolates. Hence, the aim of the study is to evaluate the changes in markers 80 
of inflammation in overweight subjects after 10-week ingestion of broccoli sprouts as 81 
well as to assess the bioavailability of glucosinolates to correlate the changes observed.  82 
 83 
MATERIAL AND METHODS  84 
Study design  85 
We performed an interventional follow-up study to evaluate the effect of the daily 86 
consumption of broccoli sprouts during 10 weeks (70 days).  87 
The study was performed according with the Helsinki Declaration of Human Studies 88 
and approved by the Ethical Committee of the Catholic University of Murcia as well as 89 
the Bioethics Sub-Committee of the CSIC’ Department of Ethics for the AGL-2013-90 
46247-P project registered also at ClinicalTrials.gov ID NCT 03390855. Volunteers 91 
(n=40; 21 men, 19 women) were recruited in the Catholic University of Murcia 92 
(UCAM) and all of them were informed on the characteristics of the study and they 93 
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signed the written-informed consent. The inclusion criteria were: BMI within the 94 
overweight range according to the World Health Organization criteria (24.9-29.9 95 
kg/m2), aged 35-55 years, taking no vitamins, supplements or medication during the 96 
previous two months; no-smoking. The exclusion criteria were: diagnosed diseases as 97 
hypertension and cardiovascular pathologies, diabetes, hepatic, gastrointestinal and 98 
renal diseases, as well as the intake of drugs related to these pathologies, vegetarian 99 
diet, pregnancy or breastfeeding. Dietetic and life style habits were recorded from all 100 
participants.  101 
There were no drop-outs during the whole period of study and no adverse effects were 102 
reported due to the broccoli sprout ingestion. Physical parameters of the volunteer at the 103 
beginning of the study are listed in Table 1.  104 
One week before the beginning of the intervention period, subjects were asked to avoid 105 
the consumption of Brassica vegetables (broccoli, radish, cauliflower, Brussel sprouts, 106 
mustards, among others) and their derived products, and to follow a well-balanced diet 107 
(based on Mediterranean diet), with no other food restriction criteria. These dietary 108 
instructions were maintained during the entire period of study. Besides, they were 109 
requested to record any sign of adverse effect, illness or deviation of the experimental 110 
diet. The subjects maintained their usual lifestyles during the study. 111 
On the first day, participants were given the portions of fresh broccoli sprouts to be 112 
taken for the whole week (7 trays of broccoli sprouts of 30 g each) and each week they 113 
had an appointment to provide them the fresh products. The intervention consisted on a 114 
10-week period which included daily consumption of a portion (30 g) of raw, fresh 115 
broccoli sprouts. This amount is consistent with a half- serving [11]. Subjects were 116 
instructed to ingest 1 tray per day and to keep the trays refrigerated (4º C) at home. The 117 
intake of the broccoli sprouts was included in their normal daily diet and no specific 118 
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time of consumption was established, with the only limitation of avoid cooking of the 119 
sprouts and to consume them fresh. Cooking procedures can affect the content of 120 
glucosinolates as well as their bioavailability [12, 13] and therefore some recipes were 121 
provided to the participants to facilitate the intake of the sprouts without affecting the 122 
phytochemical composition and absorption. We gave instructions to the volunteer of not 123 
cooking broccoli sprouts but of consuming them in raw manner. They included the 124 
sprouts in vegetable salads, cold pasta salads or in cold sandwiches with different 125 
combinations of the following ingredients: cheese, ham, tomato, lettuce, grilled pork or 126 
grilled vegetables (in both cases the sprouts should be added after the grill and once the 127 
ingredient was lukewarm).  It could also be included in burgers, as the “Californian 128 
style burger”, which ingredients are broccoli sprouts, bacon, avocado, tomato, burger 129 
and bread. Other recipes include elaboration of “Gazpacho” (Spanish cold soup made 130 
with vegetables as tomato, cucumber, green pepper, onion, oil, vinegar and salt), or 131 
mixed with smashed potatoes with melted cheese, or mixed with bread and spreadable 132 
cheese. In all cases it was important to use in cold or warm temperatures so that the 133 
glucosinolates were preserved.  134 
After the intervention period, a follow-up recovery period for all subjects continued for 135 
other 90 days with no ingestion of broccoli sprouts.   136 
Fasting blood samples and 24-h urine samples were taken on day 0 (D0: just before 137 
starting the intervention), day70 (D70: end of intervention period), day 90 (D90: 20 138 
days after end of intervention) and 160 (D160: 90 days after end of intervention). Blood 139 
samples were collected from each subject by venipuncture from the antecubital vein; 3 140 
mL were placed in heparin tubes and centrifuged at 10000 rpm for 10 min at 4ºC. 141 
Plasma was aliquoted and stored at -80ºC until analysis. Analysis were performed once 142 
each period was finished and in the same batch to minimize analytical variations. The 143 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
total volume of the 24h-urine was recorded to calculate the absolute amounts of the 144 
compounds and metabolites excreted in the study period and aliquots were frozen at -145 
80ºC for further analysis. Body weight and percentage of fat mass were measured as 146 
well and BMI calculated in each sampling time point.   147 
Broccoli sprouts 148 
Raw, fresh broccoli sprouts (Brassica oleracea var. italica) were supplied by 149 
Aquaporins&Ingredients, S.L (Alcantarilla, Murcia, Spain). The sprouts were 150 
biostimulated with methyl jasmonate 250 µM, for 4 days previous to delivery, in order 151 
to increase up to 2-fold levels the production of bioactive compounds, according to a 152 
protocol previously validated [10]. In that study we performed some tests on elicitation 153 
and seed priming to enrich the broccoli sprouts in glucosinolates. We used the elicitor 154 
methyl jasmonate (MeJA) by priming the seeds as well as by spraying daily over the 155 
cotyledons from day 4 to 7 of germination. We observed that MeJA at concentrations of 156 
250 µM act as stressor in the plant and enhances the biosynthesis of the phytochemicals 157 
glucosinolates. Compared to control plants without MeJA treatment, the content of 158 
compounds as the aliphatic glucosinolate glucoraphanin was enhanced up to a 70 % and 159 
similar increases were observed with glucoiberin or glucobrassicin. In this way, we 160 
improved the content of these health-promoting compounds. Other nutritional facts did 161 
not change with these treatments.  162 
Three trays of sprouts were collected once a week during the study, frozen and 163 
lyophilized prior to analysis on glucosinolates and isothiocyanates, as previously 164 
described [2]. The phytochemicals (glucosinolates) provided by the broccoli sprouts are 165 
summarized in Table 2. 166 
Biochemical analysis  167 
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Markers of inflammation as IL-6, C-reactive protein, IL-1β and TNF-α in plasma were 168 
determined in our laboratory using high-sensitivity ELISA kits. ichromaTM hsCRP kits 169 
were purchased from Boditech Meed Inc.’s. Human IL-6 ELISA high sensitivity kits 170 
were from BioVendor. Human IL-1β high sensitivity ELISA kits and human TNF-α 171 
high sensitivity ELISA kits were acquired from IBL International GmbH Instrumental.  172 
Analysis of glucosinolates and isothiocyanates in urine and plasma  173 
Levels of glucosinolates, isothiocyanates and their metabolites (GRA, IB, SFN, SFN-174 
GSH, SFN-NAC, SFN-CYS, I3C, 3,3-DIM) were measured in urine by a rapid, 175 
sensitive and high throughput UHPLC-QqQ-MS/MS [14]. All LC-MS grade solvents 176 
were obtained from J.T. Baker (Phillipsburg, New Jersey, U A). The standards of 177 
Sulphoraphane, SFN-glutathione, SFN-cysteine and SFN-N-acetylcisteine (SFN, SFN-178 
GSH, SFN-CYS, SFN-NAC, respectively) and Iberin (IB), Indole-3-carbinol (I3C) and 179 
3,3-Diindolyl-methane (DIM_3_3) were from SantaCruz Biotech (CA, USA).  180 
Glucoraphanin (GRA) was obtained from Phytoplan (Diehm & Neuberger GmbH, 181 
Heildelberg, Germany).  182 
Urine and plasma samples were extracted using SPE Strata-X cartridges (33um 183 
Polymeric Strong Cation) following manufacturer’s instructions (Phenomenex, 184 
Torrance, CA, USA). The cartridges were preconditioned with 2 mL of methanol and 185 
equilibrated with 2 mL of water:formic acid (98:2, v/v). Samples (400 µL) were diluted 186 
with 2 mL water:formic acid (98:2, v/v) and loaded into the column. SPE cartridges 187 
were washed with 2 mL water:formic acid (98:2, v/v). Elution of target metabolites was 188 
performed with 1 mL of methanol/formic acid (98:2, v/v). Samples eluted were dried 189 
using a SpeedVac concentrator (Savant SPD121P, Thermo Scientific, Massachusetts, 190 
USA). The extracts were reconstituted in 200 µL of mobile phases  A/B (90:10, v/v) and 191 
filtered with PTFE 0.22 µm filters  Chromatographic separation was carried out using a 192 
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ZORBAX Eclipse Plus C-18 (2.1 x 50 mm, 1.8 µm) (Agilent Technologies) and the 193 
mobile phases employed were: solvent A ammonium acetate, 13 mM (pH 4 with acetic 194 
acid) and solvent B acetonitrile/acetic acid (99.9:0.1 v/v) as previously described  195 
[15].Twenty microliters of each sample were acquired in a Agilent Technologies 196 
UHPLC-1290 Series coupled to a 6460 QqQ-MS/MS (Agilent Technologies, 197 
Waldbronn, Germany). Compounds were identified and quantified using MRM 198 
transitions and positive or negative ESI mode for confirmation of the target analytes, 199 
compared to available external standards  [14]. Standard curves were prepared freshly 200 
every day of analysis. 201 
Statistical analysis 202 
Continuous variables were summarised with means and standard deviations while 203 
qualitative variables were summarised with proportions. We estimated the relative 204 
change on the continuous biomarkers (weight, BMI, body fat, IL_6, C-reactive protein 205 
and 3,3-DIM), between the different periods (before and after Broccoli ingestion) using 206 
linear regression models. Additional models were run controlling for age and sex in 207 
case these variables were confounding the effect of the broccoli. We then compared the 208 
proportion of samples with detectable metabolites in sulphoraphane pathway (SFN, 209 
SFN-CYS and SFN-NAC) between visits. We studied the association between changes 210 
observed in body fat mass, IL6 and C-reactive protein (outcome variables) and changes 211 
in metabolites 3,3-DIM, SFN-NAC, SFN-CYS and SFN (explanatory variables) using 212 
linear regression models. Data were analysed using R (3.4.1. version) software package. 213 
RESULTS  214 
Bioactive compounds in broccoli sprouts 215 
Broccoli sprouts from each of the 10 weeks of the study were characterized for their 216 
glucosinolate (GLS) contents (Table 2). Results are presented as the serving portion 217 
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(30g) consumed daily by the volunteers. The major aliphatic glucosinolate in broccoli 218 
sprout detected was glucoraphanin (GRA, 4-methyl-sulphinylbutyl glucosinolate) and 219 
the major indolic glucosinolate detected was neoglucobrassicin (NGB, 1-methoxy3-220 
indolylmethyl glucosinolate). Total concentration of aliphatic glucosinolates was 80.50 221 
mg/30 g f.w., equivalent to 6.22 µmol/g fresh weight or 65.47 µmol/g dry weight. This 222 
concentration was two-fold higher than indolic glucosinolates (40.62 mg/30 g f.w., 223 
equivalent to 2.88 µmol/g fresh weight or 30.32 µmol/g dry weight). Volunteers 224 
consumed an average of 51 mg (117 µmol) and 20 mg (42 µmol) of glucoraphanin and 225 
neoglucobrassicin, respectively, on a daily basis, during the 70 days of the dietary 226 
intervention.   227 
Biological effects of broccoli sprout on markers of inflammation and body composition 228 
Baseline characteristics of volunteer are described in Table 1. Changes on plasma 229 
concentration of biomarkers at different time points of the intervention are shown in 230 
Table 3. Day 0 and day 70 refers to the first and last days of the broccoli ingestion, 231 
respectively. The days 90 and 160 refers to 20 days and 90 days of follow-up upon the 232 
broccoli dosage period, respectively.  233 
The evolution of mean values of continuous variables are shown in Table 4. The 234 
metabolite 3,3’-diindolylmethane (3,3-DIM) was included in the statistical analysis as it 235 
was detected in all volunteers, at concentrations higher than limit of quantification, 236 
hence, for statistical purposes, it was treated as a continuous variable. Evolution of 237 
ratios of continuous variables in each visit are shown in Figure 1. 238 
No significant changes were observed in weight and BMI. By contrast, body fat mass 239 
slightly decreased significantly after 70 days of broccoli consumption (ratio = 0.947, P-240 
value= 0.02586) and returned to basal levels at day 90, a state that was maintained until 241 
day 160 (P-value= 0.94899 y P-value=0.07644). 242 
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Plasma interleukine-6 (IL-6) concentrations decreased significantly (by 38 %) after 70 243 
days of broccoli ingestion as well, respect to basal value (ratio=0.381, P-value < 244 
0.00001). Moreover, these lower levels continue to significantly decrease after 20 days 245 
of ceasing broccoli ingestion (ratio = 0.195, P-value< 0.00001). At 90 days of the 246 
follow up period (day 160), levels returned somewhat but without returning to baseline 247 
values (ratio=0.472, P-value= 0.00000). Figure 2 illustrates how the changes in IL-6, 248 
during broccoli intake, depends on baseline values. The negative slope of the regression 249 
line indicates that volunteer with higher concentrations at baseline tend to lose more 250 
concentration of this biomarker. Decreases in C-reactive protein were also observed, 251 
during broccoli ingestion period (ratio = 0.592, P-value= 0.00915). Shortly in the 252 
follow-up period, levels returned to baseline conditions (P-value=0.92162 and P-253 
value=0.72756, at 90 and 160 days, respectively).  254 
These results did not substantially change when we repeated the regression models 255 
adjusting for age and sex. TNFα and IL-1β were detected in a small number of samples 256 
and most of them below the limit of quantification, hence no valid conclusions can be 257 
inferred and data have not been considered for statistical purposes.  258 
Bioavailability and metabolism of glucosinolates and isothiocyanates 259 
Some glucosinolates and isothiocyanates, as glucoraphanin, glucoiberin, iberin, 260 
glucoerucin, erucin and glucobrassicin were absent in the urine samples. Indole-3-261 
carbinol was detected only after broccoli ingestion in low quantities and in 50 % of 262 
samples. In contrast, the metabolite 3,3’-diindolylmethane (3,3-DIM) was detected and 263 
quantified in all volunteers and for statistical purposes it was treated as a continuous 264 
variable. It increased significantly during broccoli ingestion (ratio = 1.947, P-value < 265 
0.00001). Shortly in the follow-up period, levels returned to baseline conditions (P-266 
value=0.10484 and P-value=0.12312, at 90 and 160 days, respectively). 267 
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Metabolites from sulphoraphane pathway are present in 24 h-urine samples (Table 3); 268 
the metabolite at higher amount was SFN-NAC (mean concentration 2.0301 µM, 269 
corresponding to 3.21 µmol/24 h), whereas SFN was the compound with the lowest 270 
excretion (0.543 µM, corresponding to 0.77 µmol/24 h). The sum of SFN, SFN-NAC 271 
and SFN-CYS was ~ 5.11 µmol/24 h. Considering an amount of GRA of 117 µmol by 272 
serving, a 4 % on average was metabolized through mercapturic acid pathway.  273 
Figure 3 shows the proportion of individuals in which the metabolites have been 274 
detected and quantified at each visit and Figure 4 shows the differences of these 275 
proportions from baseline with their confidence intervals. The percentage of individuals 276 
where SFN-NAC is detected increases significantly during broccoli intervention (45% 277 
increase; P-value = 0.00001). Afterwards, the percentage diminishes although it is 278 
statistically different from baseline (32.5 % difference; P-value = 0.00303). At 160 279 
days, no significant differences from baseline are observed (P-value = 0.07139). Similar 280 
behaviour is detected with SFN-CYS and SFN. Percentages increased during broccoli 281 
ingestion (67.5 % increases in SFN-CYS P-value = 0.0000; 82.5 % increases in SFN; P-282 
value < 0.0001). Afterwards, the percentages of individuals detected decreased to 283 
baseline conditions (P-value = 0.43858 and P=value 0.26355 for SFN-CYS and SFN, 284 
respectively). This behaviour is maintained for the longer period at 160 days (P-value = 285 
0.29330 and P=value 0.73532, respectively). SFN-GSH was detected in very few 286 
samples of volunteer during broccoli ingestion (data not included), hence, it has not 287 
been considered for statistical purposes. 288 
The decrease in IL-6 levels was significantly related to the increase in 24 h-urine SFN 289 
levels (p=0.03319). In case of C-reactive protein, the decrease was significantly related 290 
to the increases in 24 h-urine SFN-NAC (p=0.04783) and SFN-CYS (p=0.04116). 291 
(Supp. Table-6). 292 
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 293 
 294 
DISCUSSION  295 
We conducted a human intervention study to test whether regular consumption of 296 
broccoli sprouts improves inflammatory biomarkers in overweight subjects. Adipose 297 
tissue is related to higher secretion of pro-inflammatory cytokines as TNF-α and IL-6 298 
and elevated levels of these proteins have been described in overweight individuals [16, 299 
17]. These proteins are linked to several disease states [18] and C-reactive is an 300 
important predictive marker of cardiovascular events [19]; hence the reduction of their 301 
levels with dietary intervention could contribute to a better prognosis on obesity-302 
associated disorders. In our study we observed a noticeable anti-inflammatory effect 303 
with the ingestion of broccoli sprouts, with a significant reduction by 38 % and 59 % in 304 
IL-6 and C-reactive protein concentrations, respectively.  305 
Clinical studies on human participants on the anti-inflammatory properties of Brassica 306 
products are scarce. Our research group has previously described a significant decrease 307 
on markers of inflammatory processes, as the metabolites tetranor-PGEM (from 308 
prostaglandins E1 and E2) and 11 β-PGF2α (from prostaglandin D2) after consumption 309 
of a single portion of broccoli sprouts [20]. Other authors have reported decreases on C-310 
reactive protein levels by 48 % after 10-day broccoli intake (250 g/day) in smokers, 311 
confirming our results; however, no changes on IL-6 levels were detected [21]. 312 
Decreases in IL-6 and C-reactive protein were also observed after 14 days of 313 
cruciferous consumption [22], but the amounts used (7g/kg body weight, 14 g/kg body 314 
weight) far exceeded those of our experiment.  315 
Differences in population studied, study design, type of Brassica or amount of product 316 
consumed, could explain the different results observed. Our broccoli sprouts contained 317 
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significant quantities of aliphatic glucosinolates as glucoraphanin, glucoiberin and 318 
glucoerucin, which derive from the aminoacid methionine, as well as indolic 319 
glucosinolates as methoxy and hydroxy derivatives of glucobrassicin, that derive from 320 
the aminoacid tryptophan. Broccoli sprouts are especially rich in glucoraphanin (up to 321 
10-fold above adult organ (inflorescence) levels) that drop with the plant growing, as 322 
the plant material increases without concomitant synthesis of glucoraphanin [23]. 323 
Hence, potential beneficial concentrations are easier to achieve with dietary quantities 324 
of sprouts vs broccoli heads (inflorescences).  325 
Levels of glucosinolates and their metabolites isothiocyanates were measured in 24h-326 
urine by UHPLC-MS/MS in order to ascertain the consumption of broccoli and with the 327 
aim to find out if any metabolite is related to the changes in the biochemical parameters 328 
observed. We did not observe significant levels of intact glucosinolates in 24 h-urine 329 
samples, being explainable as these compounds suffer extensive modifications prior to 330 
absorption in the gut. They are present in the intact plant as glucosides and, upon tissue 331 
damage, the enzyme myrosinase catalyses their rapid hydrolysis of the glucose moiety 332 
[24]. The aglycone of each glucosinolate suffers further hydrolytic metabolism to 333 
isothiocyanate in the gastrointestinal tract by gut microbiota; these compounds are then 334 
absorbed by enterocytes and distributed systemically [25]. In particular, the 335 
isothiocyanate sulphoraphane (1-isothiocyanate-4-methyl-sulfinylbutane) is formed 336 
from the glucosinolate glucoraphanin (4-methyl-sulphinylbutyl glucosinolate). 337 
Therefore, isothiocyanates are the compounds mainly present in human tissues to which 338 
can be attributed the biological activities.  339 
In humans, the isothiocyanates are metabolized via the mercapturic acid pathway. 340 
Conjugation with glutathione is catalysed by glutathione transferase and GSH-341 
conjugates are metabolized rendering SFN-CYS and SFN-NAC. It has been proven that 342 
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polymorphisms of these enzymes have a significant impact on ITC metabolism [26]. 343 
From the results described, the metabolites SFN-NAC, SFN-CYS and SFN can be 344 
considered as good markers of ingestion, as their presence is related only with the 345 
broccoli period, indicating the compliance of the experimental diet.  346 
Concerning indole glucosinolates, indole-3-carbinol (I3C) is released by hydrolysis of 347 
glucobrassicin (3-indolyl-methylglucosinolate) by myrosinase action. This type of 348 
indole glucosinolates are present in seeds, mature plant and some sprouts cultivars, but 349 
are not commonly present in all Brassica varieties [27, 28]. After ingestion, I3C is 350 
modified by the acidic pH in the stomach and dimerizes to 3,3’-diindolylmethane (3,3-351 
DIM) [29]. Hence, the presence of 3,3-DIM in the 24 h-urine samples is related to the 352 
metabolism of glucobrassicin derivatives present in our broccoli sprouts.  353 
The increases on broccoli metabolites were significantly related to the decreases in IL-6 354 
and C-reactive protein levels, what suggests their implication in the modulation of these 355 
pro-inflammatory proteins. Studies on cellular models have shown that the mechanism 356 
of interaction is common in isothiocyanates and similar to that of endogenous hormones 357 
as steroids or vitamins A and D. This type of compounds possesses electrophile groups 358 
that interact with nucleophilic moieties of transcription factors, down- or up-regulating 359 
their activity [30]; it has been shown that sulphoraphane interacts with the redox-360 
sensitive transcription factor Nrf2, to permit its translocation into the nucleus, where it 361 
binds to the antioxidant response element (ARE) and activates the synthesis of proteins 362 
related to the response to stress, as phase II detoxification enzymes and quinone 363 
reductases [31-34]. Besides, SFN inhibits activation of NF-κβ, a central transcription 364 
factor in inflammation process and the gene expression of proinflammatory mediators 365 
[34, 35]. This signalling pathway is redox sensitive as depends on the balance between 366 
ROS intracellular concentration and GSH levels. Changes on GSH levels by SFN may 367 
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influence in this anti-inflammatory action. Other authors observed an anti-inflammatory 368 
effect by induction of Nrf2-pathway of broccoli sprout extract in human skin [36] and 369 
nasal lavage cells [32] in healthy subjects as well as in patients with chronic obstructive 370 
pulmonary disease (COPD) [37].   371 
3,3’-DIM has shown to reduce transcriptional activity of NF- κβ, what results in lower 372 
levels of inflammatory mediators as IL-6, in activated macrophages [38] as well in 373 
different models of inflammation in mice [39, 40]. It has been pointed out the possible 374 
synergistic interaction of both SFN and 3,3’-DIM [7] and the isothiocyanates erucin and 375 
sulphoraphane are interconvertible [41], so that the anti-inflammatory effects observed 376 
with broccoli sprouts intake are likely due to the combined effects of all the hydrolysis 377 
products of glucosinolates.  378 
Concerning anthropometric parameters, after 10 week of the daily consumption of 379 
broccoli sprouts, weight and body mass index were not altered; however, body fat mass 380 
significantly decreased with broccoli intervention. It has been described that the 381 
metabolite I3C decreases adipogenesis by supressing pathways of lipid accumulation 382 
mediated by PPARγ [42]; however, we did not detect I3C in 24 h-urine as it is mainly 383 
excreted in its metabolite 3,3’-DIM. We did not observe a significant correlation 384 
between the increase in 3,3’-DIM and the decrease in fat mass; no further experiments 385 
were performed to corroborate an additional hypothesis about the effects on 386 
adipogenesis.  387 
A limitation of this study is the lack of a parallel randomised control group which would 388 
be ideal to stablish causality links between broccoli intakes and the change in biomarker 389 
levels. The post-intervention follow up is not an ideal control period as several other 390 
factors might have changes in the individuals or the environment. However, the strong 391 
changes observed in the inflammatory markers at the end of the intervention and their 392 
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recuperation afterwards could be an indication of the beneficial effect of the broccoli 393 
that will have to be tested in a proper trial. On the other hand, overweight is frequently 394 
associated with other pathologies as hypertension, cardiovascular events, insulin 395 
resistance or type 2 diabetes and, due to the complex interactions among them, we 396 
limited the study to people with overweight status according to WHO criteria, but 397 
without any pathology or clinical disorder. Hence, our result can only be extrapolated to 398 
these type of population and not to the overall that could include people with some 399 
concomitant pathologies.  400 
 401 
 402 
CONCLUSIONS 403 
The consumption of broccoli sprouts in a real dietary serving is able to affect IL-6 and 404 
C-reactive protein levels in overweight subjects, hence attenuating chronic 405 
inflammation. Further research with broccoli sprouts including other biomarkers and 406 
mechanistic studies are necessary to elucidate the role of this healthy rich and nutritious 407 
food product, but these promising results support the current evidence on the properties 408 
of this Brassica specie for disease prevention. 409 
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FIGURE LEGENDS 563 
Figure 1. Evolution of ratios of continuous variables in each visit according to model 564 
(1): a) changes in weight, BMI and body fat mass; b) changes in IL-6 and C-reactive 565 
protein levels 566 
Figure 2. Example of how changes in IL-6 during broccoli intake depends on baseline 567 
values of IL-6 (variables log-transformed). 568 
Figure 3. Proportion of individuals and 95 % IC of metabolites detected at each visit  569 
Figure 4. Changes in binary variables over periods 570 
 571 
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Table 1. Baseline characteristics of volunteer (n=40; 21 men, 19 women) 
 
Variable Mean ± standard deviation  
Age (years) 46 ± 6 
Height (m) 1.72 ± 0.08 
Weight (kg) 85.8 ± 16.7 
BMI (kg/m2) 28.9 ± 4.0 
Body fat mass (%) 30.34 ± 7.54 
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Table 2. Glucosinolate contents in broccoli sprouts daily portions (mg/30 g F.W) 
 
 Mean ± Standard deviation 
(n=3) 
Glucoiberin (GIB) 19.28 ± 0.98 
Glucoraphanin (GRA) 51.08 ± 1.06 
4-Hydroxiglucobrassicin (HGB) 3.67 ± 0.41 
Glucoerucin (GER) 10.14 ± 1.20 
Glucobrassicin (GBS) 9.69 ± 0.95 
4-Methoxyglucobrassicin (MBG) 7.14 ± 0.61 
Neoglucobrassicin (NBG) 20.11 ± 1.66 
Aliphatic Glucosinolates (Σ) 80.50 ± 2.18 
Indolic Glucosinolates (Σ) 40.62 ± 2.07 
Total (Σ) 121.11 ± 4.00 
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Table 3. Changes observed with broccoli treatment as well as during follow-up period. 
Values are expressed as mean (confidence interval 95 %) 
 Variable Day 0 Day 70 Day 90 Day 160 
 Weight (kg) 85.79 
(80.38–91.20) 
85.69 
(80.42–90.95) 
83.83 
(79.47-88.18) 
84.04 
(79.66-88.41) 
 BMI (kg/m2) 28.88 
(27.56-30.20) 
28.93 
(27.63-30.23) 
28.49 
(27.40-29.57) 
28.60 
(27.52-29.68) 
 Body fat mass (%) 30.34 
(27.29-33.39) 
29.32 
(26.93-31.71) 
30.29 
(27.87-32.72) 
32.09 
(29.69-34.49) 
 IL-6 (pg/mL) 4.76 
(4.21-5.31) 
2.11 
(1.61-2.61) 
1.20 
(0.88-1.52) 
2.66 
(1.89-3.44) 
 C-reactive protein  
(µg/mL) 
2.42 
(1.45-3.40) 
1.52 
(0.70-2.34) 
1.92 
(1.02-2.82) 
2.32 
(1.07-3.56) 
 SFN-NAC (µM) 0.193 
(0.00-0.41) 
2.301 
(1.85-2.75) 
0.023 
(0.01-0.04) 
0.094 
(0.00-0.19) 
 SFN-CYS (µM) 0.116 
(0.00-0.26) 
0.800 
(0.57-1.03) 
0.078 
(0.00-0.22) 
0.081 
(0.00-0.19) 
 3,3-DIM (µM) 0.484 
(0.38-0.59) 
0.707 
(0.61-0.80) 
0.449 
(0.33-0.57) 
0.461 
(0.36-0.56) 
 SFN (µM) 0.098 
(0.00-0.23) 
0.543 
(0.40-0.69) 
0.038 
(0.00-0.13) 
0.022 
(0.01-0.03) 
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Table 4. Evolution of mean values (ratios) on the time points * 
 
Variable Mean Ratio 95% CI P-value 
Weight (kg) 86.141    
From D0 to D70 86.346 1.002 (0.997 to 1.008) 0.38388 
From D0 to D90 85.983 0.998 (0.987 to 1.010) 0.74963 
From D0 to D160 86.424 1.003 (0.994 to 1.012) 0.45589 
Body mass index (kg/m2) 28.877    
From D0 to D70 28.945 1.002 (0.997 to 1.008) 0.39007 
From D0 to D90 28.797 0.997 (0.986 to 1.009) 0.62441 
From D0 to D160 28.971 1.003 (0.994 to 1.012) 0.46125 
Body fat mass (%) 28.834    
From D0 to D70 27.298 0.947 (0.903 to 0.993) 0.02586 
From D0 to D90 28.795 0.999 (0.956 to 1.043) 0.94899 
From D0 to D160 29.955 1.039 (0.996 to 1.084) 0.07644 
IL_6 (pg/mL) 4.594    
From D0 to D70 1.748 0.381 (0.298 to 0.486) 
 <0.00001 
From D0 to D90 0.896 0.195 (0.149 to 0.255) 
 <0.00001 
From D0 to D160 2.170 0.472 (0.366 to 0.609) 
 <0.00001 
C-reactive protein (µg/mL) 1.431    
From D0 to D70 0.847 0.592 (0.405 to 0.865) 0.00915 
From D0 to D90 1.459 1.020 (0.677 to 1.536) 0.92162 
From D0 to D160 1.553 1.085 (0.665 to 1.771) 0.72756 
DIM_3_3 (µM) 0.334    
From D0 to D70 0.650 1.947 (1.705 to 2.223) <0.00001 
From D0 to D90 0.335 0.757 (0.539 to 1.063) 0.10484 
From D0 to D160 0.376 0.850 (0.689 to 1.048) 0.12312 
 
*: data are adjusted by baseline levels 
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Figure 4.   
